Macrophage migration inhibitory factor: A potential marker for cancer diagnosis and therapy

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1737-1744

  Babu, Spoorthy N ^a   Chetal, Gaurav ^a   Kumar, Sudhir ^a  

^a IGNOU I2IT Centre of Excellence for Advanced Education and Research   (India)

Author keywords

Hypoxia; Immune suppression; Metastasis; MIF; Neoplasia; P53

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR MARKER;

CYTOLOGY; HUMAN; MACROPHAGE; METABOLISM; NEOPLASM; REVIEW;

HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872677274     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1737     Document Type: Article

References (101)

1. Aalamian M, Pirtskhalaishvili G, Nunez A, et al (2001). Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate, 46, 68-5.
2. Al-Abed Y, VanPatten S (2011). MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Med Chem, 3, 45-63.
3. Bach JP, Rinn B, Meyer B, Dodel R, Bacher M (2008). Role of MIF in inflammation and tumorigenesis. Oncology, 75, 127-3.
4. Bacher M, Schrader J, Thompson N, et al (2003). Up-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme. Am J Pathol, 162, 11-7.
5. Bando H, Matsumoto G, Bando M, et al (2002). Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res, 93, 389-6.
6. Baugh JA, Chitnis S, Donnelly SC, et al (2002). A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun, 3, 170-6.
7. Baugh JA, Gantier M, Li L, et al (2006). Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem Biophys Res Commun, 347, 895-3.
8. Bergers G, Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 3, 401-10.
9. Bernhagen J, Krohn R, Lue H, et al (2007). MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med, 13, 587-6.
10. Bifulco C, McDaniel K, Leng L, Bucala R (2008). Tumor growth-promoting properties of macrophage migration inhibitory factor. Curr Pharm Des, 14, 3790-801.
11. Binsky I, Haran M, Starlets D, et al (2007). IL-8 secreted in a macrophage migration-inhibitory factor- and CD74- dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A, 104, 13408-3.
12. Bondza PK, Metz CN, Akoum A (2008). Macrophage migration inhibitory factor up-regulates alpha(v)beta(3) integrin and vascular endothelial growth factor expression in endometrial adenocarcinoma cell line Ishikawa. J Reprod Immunol, 77, 142-1.
13. Bornstein G, Ganoth D, Hershko A (2006). Regulation of neddylation and deneddylation of cullin1 in SCFSkp2 ubiquitin ligase by F-box protein and substrate. Proc Natl Acad Sci U S A, 103, 11515-0.
14. Bucala R, Donnelly SC (2007). Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity, 26, 281-5.
15. Budarf M, McDonald T, Sellinger B, et al (1997). Localization of the human gene for macrophage migration inhibitory factor (MIF) to chromosome 22q112. Genomics, 39, 235-6.
16. Calandra T, Bernhagen J, Metz CN, et al (1995). MIF as a glucocorticoid-induced modulator of cytokine production. Nature, 377, 68-1.
17. Cardozo T, Pagano M (2004). The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol, 5, 739-51.
18. Cheng RJ, Deng WG, Niu CB, Li YY, Fu Y (2011). Expression of macrophage migration inhibitory factor and CD74 in cervical squamous cell carcinoma. Int J Gynecol Cancer, 21, 1004-2.
19. Claassen GF, Hann SR (2000). A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. Proc Natl Acad Sci U S A, 97, 9498-3.
20. Cohen S, Shoshana OY, Zelman-Toister E, et al (2012). The Cytokine Midkine and Its Receptor RPTPzeta Regulate B Cell Survival in a Pathway Induced by CD74. J Immunol, 188, 259-9.
21. Colombo MP, Mantovani A (2005). Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res, 65, 9113-6.
22. Conroy H, Mawhinney L and Donnelly SC (2010). Inflammation and cancer: macrophage migration inhibitory factor (MIF)- -the potential missing link. QJM, 103, 831-6.
23. Dhingra S, Feng W, Brown RE, et al (2011). Clinicopathologic significance of putative stem cell markers, CD44 and nestin, in gastric adenocarcinoma. Int J Clin Exp Pathol, 4, 733-1.
24. El-Omar EM, Ng MT, Hold GL (2008). Polymorphisms in Tolllike receptor genes and risk of cancer. Oncogene, 27, 244-2.
25. Fingerle-Rowson G, Petrenko O (2007). MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Cell Div, 2, 22.
26. Gooding JM, Yap KL, Ikura M (2004). The cadherin-catenin complex as a focal point of cell adhesion and signalling: new insights from three-dimensional structures. Bioessays, 26, 497-11.
27. Guo YS, Dai YP, Li W, Liu LD (2011). Expression and significance of macrophage migration inhibitory factor in bladder urothelial cell carcinoma. Zhonghua Zhong Liu Za Zhi, 33, 28-1.
28. Hagemann T, Robinson SC, Thompson RG, et al (2007). Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther, 6, 1993-2.
29. Hartwell LH, Kastan MB (1994). Cell cycle control and cancer. Science, 266, 1821-8.
30. Haupt Y, Maya R, Kazaz A, Oren M (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-2
31. Hudson JD, Shoaibi MA, Maestro R, et al (1999). A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med, 190, 1375-2.
32. Hurlin PJ (2005). N-Myc functions in transcription and development. Birth Defects Res C Embryo Today, 75, 340-52.
33. Ichihara E, Kiura K, Tanimoto M (2011). Targeting angiogenesis in cancer therapy. Acta medica Okayama, 65, 353-2.
34. Jang BI, Li Y, Graham DY, Cen P (2011). The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer. Gut Liver, 5, 397-5.
35. Johnson JL, Pillai S, Pernazza D, et al (2011). Regulation of Matrix Metalloproteinase Genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res.
36. Jung H, Seong HA and Ha H (2008). Critical role of cysteine residue 81 of macrophage migration inhibitory factor (MIF) in MIF-induced inhibition of p53 activity. J Biol Chem, 283, 20383-96.
37. Kleemann R, Hausser A, Geiger G, et al (2000). Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature, 408, 211-6.
38. Kops GJ, Weaver BA, Cleveland DW (2005). On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer, 5, 773-85.
39. Krishnamachary B, Zagzag D, Nagasawa H, et al (2006). Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res, 66, 2725-1.
40. Krockenberger M, Dombrowski Y, Weidler C, et al (2008). Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol, 180, 7338-48.
41. Lane DP (1992). Cancer, p53, guardian of the genome. Nature, 358, 15-6.
42. Lapidot T, Dar A and Kollet O (2005). How do stem cells find their way home. Blood, 106, 1901-10.
43. Lee EW, Oh W and Song J (2006). Jab1 as a mediator of nuclear export and cytoplasmic degradation of p53. Mol Cells, 22, 133-40.
44. Lee H, Rhee H, Kang HJ, et al (2008). Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am J Clin Pathol, 129, 772-9.
45. Li Z, Lin SX, Liang YJ, Zong YS (2004). Effect of macrophage migration inhibitory factor (MIF) on expression of MMP- 2, MMP-9, and IL-8 in nasopharyngeal carcinoma cell strains. Ai Zheng, 23, 130-5.
46. Libra M, Scalisi A, Vella N, et al. (2009). Uterine cervical carcinoma: role of matrix metalloproteinases (review). Int J Oncol, 34, 897-3.
47. Liu L, Ji C, Chen J, et al (2008). A global genomic view of MIF knockdown-mediated cell cycle arrest. Cell Cycle, 7, 1678-92.
48. Liu Q, Yang H, Zhang SF (2010). Expression and significance of MIF and CD147 in non-small cell lung cancer. Sichuan Da Xue Xue Bao Yi Xue Ban, 41, 85-90.
49. Lue H, Kapurniotu A, Fingerle-Rowson G, et al. (2006). Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal, 18, 688-703.
50. Lue H, Thiele M, Franz J, et al (2007). Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene, 26, 5046-59.
51. Lyapina S, Cope G, Shevchenko A, et al (2001). Promotion of NEDD-CUL1 conjugate cleavage by COP9 signalosome. Science, 292, 1382-5.
52. Madani SY, Naderi N, Dissanayake O, Tan A, Seifalian AM (2011). A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int J nanomedicine, 6, 2963-79.
53. Marhaba R, Zoller M (2004). CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol, 35, 211-31.
54. Medema RH, Macurek L (2011). Checkpoint control and cancer. Oncogene.
55. Meyer-Siegler KL Iczkowski KA, Leng L, Bucala R, Vera PL (2006). Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol, 177, 8730-9.
56. Miller SC, Huang R, Sakamuru S, et al (2010). Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem Pharmacol, 79, 1272-0.
57. Mitchell RA, Liao H, Chesney J, et al (2002). Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A, 99, 345-50.
58. Mitchell RA, Metz CN, Peng T, Bucala R (1999). Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem, 274, 18100-6.
59. Nakaya K, Nabata Y, Ichiyanagi T, An WW (2012). Stimulation of Dendritic Cell Maturation and Induction of Apoptosis in Leukemia Cells by a Heat-stable Extract from Azuki bean (Vigna angularis), a Promising Immunopotentiating Food and Dietary Supplement for Cancer Prevention. Asian Pac J Cancer Prev, 13, 607-11
60. Nakayama KI, Nakayama K (2006). Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer, 6, 369-81.
61. Nemajerova A, Mena P, Fingerle-Rowson G, Moll UM, Petrenko O (2007). Impaired DNA damage checkpoint response in MIF-deficient mice. EMBO J, 26, 987-97.
62. Nemajerova A, Moll UM, Petrenko O, Fingerle-Rowson G (2007). Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle. Cell Cycle, 6, 1030-4.
63. Nguyen MT, Lue H, Kleemann R, et al (2003). The cytokine macrophage migration inhibitory factor reduces prooxidative stress-induced apoptosis. J Immunol, 170, 3337-47.
64. Nishihira J (2000). Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res, 20, 751-62.
65. Nishihira J, Ishibashi T, Fukushima T, et al (2003). Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann N Y Acad Sci, 995, 171-2.
66. Nishihira J, Koyama Y, Mizue Y (1996). Identification of macrophage migration inhibitory factor in human leukemia HL-60 cells and its induction by lipopolysaccharide. Biochem Mol Biol Int, 40, 861-9.
67. Oda S, Oda T, Nishi K, et al (2008). Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS One, 3, 2215.
68. Oloumi A, McPhee T and Dedhar S (2004). Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase. Biochim Biophys Acta, 1691, 1-15.
69. Ong GL, Goldenberg DM, Hansen HJ and Mattes MJ (1999). Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology, 98, 296-2.
70. Pollard JW (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer, 4, 71-8.
71. Ren Y, Chan HM, Fan J, et al (2006). Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma. Oncogene, 25, 3501-8.
72. Ren Y, Chan HM, Li Z, et al (2004). Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene, 23, 4146-4.
73. Ren Y, Law S, Huang X, et al (2005). Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg, 242, 55-3.
74. Rendon BE, Roger T, Teneng I, et al (2007). Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. J Biol Chem, 282, 29910-8.
75. Rosengren E, Bucala R, Aman P, et al (1996). The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med, 2, 143-9.
76. Sen S and Hopwood V (2011). Molecular cytogenetic evidence for multistep tumorigenesis: implications for risk assessment and early detection. Cancer Biomark, 9, 113-32.
77. Shimizu T, Abe R, Nakamura H, et al (1999). High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. Biochem Biophys Res Commun, 264, 751-8.
78. Shimizu T, Nishihira J, Watanabe H, et al (2004). Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells. J Biol Chem, 279, 13729-7.
79. Shi X, Leng L, Wang T, et al (2006). CD44 is the signaling component of the macrophage migration inhibitory factor- CD74 receptor complex. Immunity, 25, 595-6.
80. Shkolnik T, Livni E, Reshef R, Lachter J, Eidelman S (1987). Comparison of two lymphokines (macrophage migration inhibition, leukocyte adherence inhibition factors) and carcinoembryonic antigen, in colorectal cancer and colonic premalignant lesions. Am J Gastroenterol, 82, 1275-8.
81. Spiller SE, Logsdon NJ, Deckard LA, Sontheimer H (2011). Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo. BMC Cancer, 11, 136.
82. Staller P, Peukert K, Kiermaier A, et al (2001). Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol, 3, 392-9.
83. Steegenga WT, van der Eb AJ, Jochemsen AG (1996). How phosphorylation regulates the activity of p53. J Mol Biol, 263, 103-3.
84. Stein R, Mattes MJ, Cardillo TM, et al (2007). CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res, 13, 5556-3.
85. Strieter RM (2005). Masters of angiogenesis. Nat Med, 11, 925-7.
86. Sun B, Nishihira J, Yoshiki T, et al (2005). Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res, 11, 1050-8.
87. Sun HW, Bernhagen J, Bucala R, Lolis E (1996). Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A, 93, 5191-6.
88. Sun HW, Swope M, Cinquina C, et al (1996). The subunit structure of human macrophage migration inhibitory factor: evidence for a trimer. Protein Eng, 9, 631-5.
89. Talos F, Mena P, Fingerle-Rowson G, Moll U, Petrenko O (2005). MIF loss impairs Myc-induced lymphomagenesis. Cell Death Differ, 12, 1319-8.
90. Tang WM, Gou X, Liu QX (2011). Expression of macrophage migration inhibition factor (MIF) in serum of patients with prostate cancer and its clinical significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 27, 97-8.
91. Thiele M and Bernhagen J (2005). Link between macrophage migration inhibitory factor and cellular redox regulation. Antioxid Redox Signal, 7, 1234-48.
92. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H (1999). p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol, 9, 661-4.
93. Veillat V, Carli C, Metz CN, et al (2010). Macrophage migration inhibitory factor elicits an angiogenic phenotype in human ectopic endometrial cells and triggers the production of major angiogenic factors via CD44, CD74, and MAPK signaling pathways. J Clin Endocrinol Metab, 95, E403-2.
94. Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B (1996). Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J, 15, 6595-4.
95. Welcker M, Orian A, Jin J, et al (2004). The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylationdependent c-Myc protein degradation. Proc Natl Acad Sci U S A, 101, 9085-90.
96. Winner M, Koong AC, Rendon BE, Zundel W, Mitchell RA. (2007). Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxiainducible factor stabilization. Cancer Res, 67, 186-3.
97. Winner M, Leng L, Zundel W, Mitchell RA (2007). Macrophage migration inhibitory factor manipulation and evaluation in tumoral hypoxic adaptation. Methods Enzymol, 435, 355-69.
98. Xu X, Wang B, Ye C, et al (2008). Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett, 261, 147-7.
99. Xue Y, Xu H, Rong L, et al (2010). The MIF -173G/C polymorphism and risk of childhood acute lymphoblastic leukemia in a Chinese population. Leuk Res, 34, 1282-6.
100. Yamasaki L, Pagano M (2004). Cell cycle, proteolysis and cancer. Curr Opin Cell Biol, 16, 623-8
101. Zheng J, Yang X, Harrell JM, et al (2002). CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol Cell, 10, 1519-6.